Exact Sciences(US:EXAS) ZACKS·2024-08-01 00:31分组1 - Exact Sciences reported a quarterly loss of $0.09 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.37, and an improvement from a loss of $0.45 per share a year ago, indicating an earnings surprise of 75.68% [1] - The company achieved revenues of $699.26 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.55% and showing an increase from $622.09 million in the same quarter last year [1] - Over the last four quarters, Exact Sciences has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [1] 分组2 - The stock has underperformed, losing about 37% since the beginning of the year, while the S&P 500 has gained 14% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $730.76 million, and for the current fiscal year, it is -$1.27 on revenues of $2.83 billion [4] - The Medical - Biomedical and Genetics industry, to which Exact Sciences belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [5]